

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kangji Medical Holdings Limited

康基医疗控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9997)

**CHANGE OF COMPANY SECRETARY AND AGENT
FOR THE ACCEPTANCE OF SERVICE OF PROCESS AND
NOTICES IN HONG KONG**

The board (the “**Board**”) of directors (the “**Directors**”) of Kangji Medical Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that with effect from May 3, 2022:

- (i) Mr. WAN Siu Keung (“**Mr. Wan**”) has been appointed as the company secretary of the Company, in place of Mr. YIN Zixin (“**Mr. Yin**”) and Ms. LEUNG Shui Bing (“**Ms. Leung**”) whose appointments have ceased on the same date; and
- (ii) Mr. Wan has been appointed as the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), in place of Ms. Leung whose appointment has ceased on the same date.

Mr. Yin and Ms. Leung have confirmed that they have no disagreement with the Board and there are no matters in relation to their resignation or termination of appointment that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Mr. Wan meets the qualification requirements for company secretary under Rule 3.28 of the Rules Governing the Listing of Securities on the Stock Exchange. The biographical details of Mr. Wan are as follows:

Mr. Wan, aged 38, joined the Group in September 2020 as a senior finance manager and he has been subsequently appointed as a director and the company secretary of Kangji Medical (Hong Kong) Limited, a wholly-owned subsidiary of the Company, in January 2022 and December 2020 respectively.

Mr. Wan has over 16 years of experience in the fields of auditing, financial management and corporate secretary. Mr. Wan worked in Deloitte Touche Tohmatsu from 2006 to 2014 and his last position was an audit manager. From April 2014 to October 2016, Mr. Wan worked in the finance department of Jiayuan International Group Limited (stock code: 2768) and its predecessor, in which he had also acted as its company secretary from July 2015 to October 2016. From October 2016 to May 2020, Mr. Wan served as the financial controller of Synertone Communication Corporation (stock code: 1613).

Mr. Wan obtained his bachelor's degree in accounting and finance from the Hong Kong University of Science and Technology in May 2006. He is a member of the Hong Kong Institute of Certified Public Accountants and a chartered financial analyst (“CFA”) of the CFA Institute.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Yin and Ms. Leung for their valuable contributions to the Company during their tenure of service and extend its warm welcome to Mr. Wan on his new appointment.

By order of the Board
Kangji Medical Holdings Limited
ZHONG Ming
Chairman

Hangzhou, PRC, May 3, 2022

As at the date of this announcement, the Board comprises Mr. ZHONG Ming, Ms. SHENTU Yinguang, Ms. Frances Fang CHOVANEC and Mr. Yin Zixin as executive Directors; Ms. CAI Li as non-executive Director; and Mr. JIANG Feng, Mr. GUO Jian and Mr. CHEN Weibo as independent non-executive Directors.